CEO & Majority Shareholder Inject $12.9M via ATM, Extending Cash Runway Amidst Increased R&D

summarizeSummary

Pulse Biosciences secured $12.9 million from its majority shareholder and CEO via an ATM offering, extending its cash runway and demonstrating strong insider confidence despite an increased net loss in Q1 2026.

check_boxKey Events

• Insider Capital Injection

  Majority shareholder Robert Duggan and CEO Paul LaViolette purchased 675,233 shares for $12.9 million through an at-the-market (ATM) offering on May 11, 2026, demonstrating strong insider conviction.

• Extended Cash Runway

  The $12.9 million capital raise, combined with existing resources, is expected to fund operating activities for at least one year, addressing near-term liquidity concerns.

• Increased R&D Investment

  Research and development expenses increased by $2.3 million to $12.6 million in Q1 2026, reflecting continued strategic investment in the nPulse Cardiac Catheter and Surgical Clamp programs.

• First Product Revenue Reported

  The company reported its first product revenue of $0.4 million in Q1 2026 from the limited market release of its Vybrance Percutaneous Electrode System.

auto_awesomeAnalysis

Pulse Biosciences reported Q1 2026 financials showing an increased net loss and cash burn, but also its first product revenue of $0.4 million. Critically, the company announced a $12.9 million capital injection from its majority shareholder and Co-Chairman, Robert Duggan, and CEO and Co-Chairman, Paul LaViolette, through an at-the-market (ATM) offering. This insider purchase significantly bolsters the company's liquidity, extending its cash runway for at least one year. The increased R&D expenses reflect continued investment in its core Nano-pulse Stimulation (NPS) technology, particularly the nPulse Cardiac Catheter and Surgical Clamp programs, which have shown compelling clinical data.